Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland

Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.2147/COPD.S37486

Indexing Status
Subject indexing assigned by NLM

MeSH
Adrenergic beta-2 Receptor Agonists /economics /therapeutic use; Aminopyridines /economics /therapeutic use; Benzamides /economics /therapeutic use; Cohort Studies; Cost-Benefit Analysis; Cyclopropanes /economics /therapeutic use; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids /economics /therapeutic use; Hospitalization /economics; Humans; Life Expectancy; Male; Markov Chains; Middle Aged; Models, Econometric; Muscarinic Antagonists /economics /therapeutic use; Phosphodiesterase 4 Inhibitors /economics /therapeutic use; Pulmonary Disease, Chronic Obstructive /drug therapy /mortality; Quality-Adjusted Life Years; Severity of Illness Index; Switzerland

AccessionNumber
22013010601

Date bibliographic record published
05/04/2013